QualityStocksNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Featured in NetworkNewsWire Editorial Highlighting Innovative Therapeutics Pipeline
Oncotelic Therapeutics (OTCQB: OTLC) announced its inclusion in a NetworkNewsWire (“NNW”) editorial titled “Innovative Therapeutics Pipeline Positions Industry for Strong Market Growth” (https://ibn.fm/WpGOO). The piece spotlights Oncotelic’s leadership in RNA-based, immunotherapy, and targeted therapeutics, addressing critical unmet needs in aggressive cancers and pediatric rare diseases. Led by chair and CEO Dr. Vuong Trieu, the company is advancing a portfolio supported by more than 500 patent applications and 75 issued patents, leveraging AI, nanomedicine, and novel clinical models to transform cancer and rare disease treatment. To view the full press release, visit https://ibn.fm/Wtn6b About Oncotelic Therapeutics Inc. Oncotelic Therapeutics is a…